IMV News and Press, IMV Inc. From 12/08/19

7/9 (77.8%) evaluable subjects exhibited clinical benefit, including three complete responses and two partial responses Reproducible survivin-specific T cell responses and favorable safety profile observed in all seven subjects that achieved clinical benefit on treatment Top-line...

IMV Inc. (“IMV” or the “Corporation”) (Nasdaq: IMV; TSX: IMV), a clinical-stage biopharmaceutical company pioneering a novel class of immunotherapies, today announced that the IMV’s executive management team will participate in two upcoming investor conferen...

IMV, Inc. (IMV) Q3 2019 Earnings Conference Call November 08, 2019, 08:00 ET Company Participants Pierre Labbé - CFO Frederic Ors - CEO & Director Conference Call Participants James Birchenough - Wells Fargo Securities David Novak - Raymond James Ltd. Joseph Pant...

IMV (NASDAQ: IMV ): Q3 GAAP EPS of -C$0.16 misses by C$0.04 . More news on: IMV Inc., Earnings news and commentary, , Read more ...

Reported preliminary data from Phase 2 basket study of DPX-Survivac in multiple solid tumors at the ESMO annual meeting, showing treatment was well-tolerated and showed signs of clinical activity Entered into research collaboration with The Wistar Institute, leveraging DPX techno...

Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB), a company focused on the development of precision immunodiagnostics and immunotherapeutics, and IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical stage biopharmaceutical company pioneering a novel class of immunotherapies, have entered a prec...

87.5% of evaluable subjects exhibited clinical benefit, including 2 complete responses and 3 partial responses All patients tested were positive for survivin and blood analysis shows strong survivin-specific T cell responses correlated with clinical responses The final conference...

Robust survivin-specific T cell responses observed in recurrent late-stage ovarian cancer in nearly all evaluable subjects Survivin-specific T cells remain active and proliferative over time, leading to T cell infiltration and the repopulation of up to 90% of the tumor microenvironment...

IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical-stage biopharmaceutical company pioneering a novel class of immunotherapies, today announced the appointment of Joanne Schindler, M.D., D.V.M. as its new Chief Medical Officer, effective November 4, 2019. Dr. Schindler will succeed Gabriela Rosu, M...

IMV Inc. (“IMV” or the “Corporation”) (Nasdaq: IMV; TSX: IMV), a clinical-stage biopharmaceutical company pioneering a novel class of immunotherapies, announced today that it will hold a conference call and webcast on Friday, November 8, 2019 at 8:00 a.m. ET to dis...